Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 198

1.

Late activation of the Raf/MEK/ERK pathway is required for translocation of the respiratory syncytial virus F protein to the plasma membrane and efficient viral replication.

Preugschas HF, Hrincius ER, Mewis C, Tran GVQ, Ludwig S, Ehrhardt C.

Cell Microbiol. 2019 Jan;21(1):e12955. doi: 10.1111/cmi.12955. Epub 2018 Oct 23.

PMID:
30223301
2.

In Vitro Models to Study Influenza Virus and Staphylococcus aureus Super-Infection on a Molecular Level.

Bruchhagen C, van Krüchten A, Klemm C, Ludwig S, Ehrhardt C.

Methods Mol Biol. 2018;1836:375-386. doi: 10.1007/978-1-4939-8678-1_18.

PMID:
30151583
3.

Late Endosomal/Lysosomal Cholesterol Accumulation Is a Host Cell-Protective Mechanism Inhibiting Endosomal Escape of Influenza A Virus.

Kühnl A, Musiol A, Heitzig N, Johnson DE, Ehrhardt C, Grewal T, Gerke V, Ludwig S, Rescher U.

MBio. 2018 Jul 24;9(4). pii: e01345-18. doi: 10.1128/mBio.01345-18.

4.

The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression.

Schräder T, Dudek SE, Schreiber A, Ehrhardt C, Planz O, Ludwig S.

Antiviral Res. 2018 Sep;157:80-92. doi: 10.1016/j.antiviral.2018.07.006. Epub 2018 Jul 7.

5.

Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound.

Bruchhagen C, Jarick M, Mewis C, Hertlein T, Niemann S, Ohlsen K, Peters G, Planz O, Ludwig S, Ehrhardt C.

Sci Rep. 2018 Jun 14;8(1):9114. doi: 10.1038/s41598-018-27445-7.

6.

IL-1β as mucosal vaccine adjuvant: the specific induction of tissue-resident memory T cells improves the heterosubtypic immunity against influenza A viruses.

Lapuente D, Storcksdieck Genannt Bonsmann M, Maaske A, Stab V, Heinecke V, Watzstedt K, Heß R, Westendorf AM, Bayer W, Ehrhardt C, Tenbusch M.

Mucosal Immunol. 2018 Jul;11(4):1265-1278. doi: 10.1038/s41385-018-0017-4. Epub 2018 Mar 15.

PMID:
29545648
7.

Investigation of supersaturation and in vitro permeation of the poorly water soluble drug ezetimibe.

Alhayali A, Selo MA, Ehrhardt C, Velaga S.

Eur J Pharm Sci. 2018 May 30;117:147-153. doi: 10.1016/j.ejps.2018.01.047. Epub 2018 Feb 2.

PMID:
29408604
8.

Staphylococcus aureus triggers a shift from influenza virus-induced apoptosis to necrotic cell death.

van Krüchten A, Wilden JJ, Niemann S, Peters G, Löffler B, Ludwig S, Ehrhardt C.

FASEB J. 2018 May;32(5):2779-2793. doi: 10.1096/fj.201701006R. Epub 2018 Jan 11.

PMID:
29401589
9.

Immunomodulatory Nonstructural Proteins of Influenza A Viruses.

Klemm C, Boergeling Y, Ludwig S, Ehrhardt C.

Trends Microbiol. 2018 Jul;26(7):624-636. doi: 10.1016/j.tim.2017.12.006. Epub 2018 Jan 17. Review.

PMID:
29373257
10.

Vemurafenib Limits Influenza A Virus Propagation by Targeting Multiple Signaling Pathways.

Holzberg M, Boergeling Y, Schräder T, Ludwig S, Ehrhardt C.

Front Microbiol. 2017 Dec 14;8:2426. doi: 10.3389/fmicb.2017.02426. eCollection 2017.

11.

Pharmacodynamics, Pharmacokinetics, and Antiviral Activity of BAY 81-8781, a Novel NF-κB Inhibiting Anti-influenza Drug.

Droebner K, Haasbach E, Dudek SE, Scheuch G, Nocker K, Canisius S, Ehrhardt C, von Degenfeld G, Ludwig S, Planz O.

Front Microbiol. 2017 Nov 2;8:2130. doi: 10.3389/fmicb.2017.02130. eCollection 2017.

12.

Inhalation Biopharmaceutics: Progress Towards Comprehending the Fate of Inhaled Medicines.

Ehrhardt C.

Pharm Res. 2017 Dec;34(12):2451-2453. doi: 10.1007/s11095-017-2304-2. Epub 2017 Nov 16.

PMID:
29147818
13.

Methylphenidate: Gender trends in adult and pediatric populations over a 7year period.

Ehrhardt C, Boucherie Q, Pauly V, Braunstein D, Ronflé E, Thirion X, Frauger E, Micallef J.

Therapie. 2017 Dec;72(6):635-641. doi: 10.1016/j.therap.2017.05.005. Epub 2017 Jul 21.

PMID:
29061293
14.

Inhalation delivery of complex drugs-the next steps.

de Kruijf W, Ehrhardt C.

Curr Opin Pharmacol. 2017 Oct;36:52-57. doi: 10.1016/j.coph.2017.07.015. Epub 2017 Aug 30. Review.

PMID:
28846876
15.

Oligopeptide Transport in Rat Lung Alveolar Epithelial Cells is Mediated by Pept2.

Gukasyan HJ, Uchiyama T, Kim KJ, Ehrhardt C, Wu SK, Borok Z, Crandall ED, Lee VHL.

Pharm Res. 2017 Dec;34(12):2488-2497. doi: 10.1007/s11095-017-2234-z. Epub 2017 Aug 22.

PMID:
28831683
16.

Expression and Activity of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Distal Lung Epithelial Cells In Vitro.

Nickel S, Selo MA, Fallack J, Clerkin CG, Huwer H, Schneider-Daum N, Lehr CM, Ehrhardt C.

Pharm Res. 2017 Dec;34(12):2477-2487. doi: 10.1007/s11095-017-2172-9. Epub 2017 May 3.

PMID:
28470471
17.

Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs.

Ehrhardt C, Bäckman P, Couet W, Edwards C, Forbes B, Fridén M, Gumbleton M, Hosoya KI, Kato Y, Nakanishi T, Takano M, Terasaki T, Yumoto R.

J Pharm Sci. 2017 Sep;106(9):2234-2244. doi: 10.1016/j.xphs.2017.04.011. Epub 2017 Apr 15. Review.

PMID:
28416418
18.

The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo.

Haasbach E, Müller C, Ehrhardt C, Schreiber A, Pleschka S, Ludwig S, Planz O.

Antiviral Res. 2017 Jun;142:178-184. doi: 10.1016/j.antiviral.2017.03.024. Epub 2017 Apr 2.

19.

Mitogen-activated protein kinases (MAPKs) regulate IL-6 over-production during concomitant influenza virus and Staphylococcus aureus infection.

Klemm C, Bruchhagen C, van Krüchten A, Niemann S, Löffler B, Peters G, Ludwig S, Ehrhardt C.

Sci Rep. 2017 Feb 14;7:42473. doi: 10.1038/srep42473.

20.

In vitro uptake and transport studies of PEG-PLGA polymeric micelles in respiratory epithelial cells.

Hu X, Yang FF, Liu CY, Ehrhardt C, Liao YH.

Eur J Pharm Biopharm. 2017 May;114:29-37. doi: 10.1016/j.ejpb.2017.01.004. Epub 2017 Jan 14.

PMID:
28093351

Supplemental Content

Loading ...
Support Center